Hemophagocytic Lymphohistiocytosis: an updated overview and management approach in the critical care setting

Amjad Almansi; Shahd Alqato; Sami Bawardi; Tariq Sabobeh; Heba Al Madanat; Obadah Alquadan; Eman Al-Antary

doi:10.58877/japaj.v2i1.119

Authors

Amjad Almansi
Shahd Alqato
Sami Bawardi
Tariq Sabobeh
Heba Al Madanat
Obadah Alquadan
Eman Al-Antary Childrens Hospital of Michigan

DOI:

https://doi.org/10.58877/japaj.v2i1.119

Abstract

Hemophagocytic lymphohistiocytosis (HLH) constitutes a rare and potentially life-threatening immunological syndrome. It manifests in both primary (genetic) and secondary (acquired) forms, exhibiting a diverse range of clinical and laboratory features, thereby posing challenges to accurate diagnosis, particularly within critical care settings. Early identification and intervention are of vital importance for improving patient survival. This article comprehensively explores the existing literature, encompassing the classification, pathophysiology, and clinical presentation of HLH. Special emphasis is placed on identifying prognostic factors, organ failure, and associated complications. Moreover, a detailed narrative of proposed management strategies, including immuno- and myelosuppressive options, is presented. Further research directions are suggested to enhance the understanding and treatment of this complex disorder.

References

Janka G. Familial and acquired hemophagocytic lymphohistiocytosis. European Journal of Pediatrics [Internet; Dec 7;166(2):95–109. DOI: 10.1007/s00431-006-0258-1. DOI: https://doi.org/10.1007/s00431-006-0258-1

Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118: 4041. DOI: https://doi.org/10.1182/blood-2011-03-278127

Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood [Internet. DOI: 10.1182/blood-2015-01-551622. DOI: https://doi.org/10.1182/blood-2015-01-551622

Parikh SA, Kapoor P, Letendre L, et al. Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. Mayo Clinic Proceedings [Internet; Apr 1;89(4):484–92. DOI: 10.1016/j.mayocp.2013.12.012. DOI: https://doi.org/10.1016/j.mayocp.2013.12.012

Henter JI, Elinder G, Öst Å. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. PubMed [Internet; Feb 1;18(1):29–33, https://pubmed.ncbi.nlm.nih.gov/1992521.

Merrill S, Naik RP, Streiff MB, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine [Internet; Aug 1;97(31):e11579. DOI: 10.1097/md.0000000000011579. DOI: https://doi.org/10.1097/MD.0000000000011579

Stéphan F, Thiolière B, Verdy E, et al. Role of Hemophagocytic Histiocytosis in the Etiology of Thrombocytopenia in Patients with Sepsis Syndrome or Septic Shock. Clinical Infectious Diseases [Internet. DOI: 10.1086/516086. DOI: https://doi.org/10.1086/516086

Lachmann G, Spies C, Schenk T, et al. Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units. Shock [Internet. DOI: 10.1097/shk.0000000000001048. DOI: https://doi.org/10.1097/SHK.0000000000001048

Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy. Best Practice & Research: Clinical Rheumatology [Internet; 7;34(4):101515. DOI: 10.1016/j.berh.2020.101515. DOI: https://doi.org/10.1016/j.berh.2020.101515

Kaplan J, Domenico I, Ward DM. Chediak-higashi syndrome. Curr Opin Hematol; Jan 1;15(1):22-9. DOI: https://doi.org/10.1097/MOH.0b013e3282f2bcce

Meeths M, Bryceson YT, Rudd E, et al. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer; Apr;54(4):563-72. DOI: https://doi.org/10.1002/pbc.22357

Seemayer TA, Gross TG, Egeler RM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res; Oct;38(4):471-8. DOI: https://doi.org/10.1203/00006450-199510000-00001

Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program; 2013: 605–611. DOI: https://doi.org/10.1182/asheducation-2013.1.605

Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol.

Morimoto A, Nakazawa Y, Ishii E. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management. Pediatr Int; Sep;58(9):817-25. DOI: 10.1111/ped.13064. DOI: https://doi.org/10.1111/ped.13064

Halyabar O, Chang MH, Schoettler ML, et al. Calm in the midst of cytokine storm: A collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatric Rheumatology 2019; 17: 1–12. DOI: https://doi.org/10.1186/s12969-019-0309-6

Meeths M, Horne A, Sabel M, et al. Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatr Blood Cancer; Feb;62(2):346-352. DOI: 10.1002/pbc.25308. DOI: https://doi.org/10.1002/pbc.25308

Risma KA, Marsh RA. Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis. J Allergy Clin Immunol Pract; Mar;7(3):824-832. DOI: 10.1016/j.jaip.2018.11.050. DOI: https://doi.org/10.1016/j.jaip.2018.11.050

Lorenz F, Klimkowska M, Pawłowicz E, et al. Clinical characteristics, therapy response, and outcome of 51 adult patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis: a single institution experience. Leuk Lymphoma; Aug 3;59(8):1840-50. DOI: https://doi.org/10.1080/10428194.2017.1403018

Créput C, Galicier L, Buyse S, et al. Understanding organ dysfunction in hemophagocytic lymphohistiocytosis. In: Applied Physiology in Intensive Care Medicine. Berlin, Heidelberg: Springer, pp. 337–347. DOI: https://doi.org/10.1007/978-3-642-01769-8_49

Hines M, Bhatt N, Talano J-AM. Diagnosis, Treatment, and Management of Hemophagocytic Lymphohistiocytosis in the Critical Care Unit. In: Critical Care of the Pediatric Immunocompromised Hematology/Oncology Patient. Cham: Springer International Publishing, pp. 159–182. DOI: https://doi.org/10.1007/978-3-030-01322-6_9

Buyse S, Teixeira L, Galicier L, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med 2010; 36: 1695–1702. DOI: https://doi.org/10.1007/s00134-010-1936-z

Seguin A, Galicier L, Boutboul D, et al. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. Chest [Internet; May;149(5):1294–301, https://linkinghub.elsevier.com/retrieve/pii/S0012369215001592. DOI: https://doi.org/10.1016/j.chest.2015.11.004

Valade S, Mariotte E, Azoulay E. Coagulation Disorders in Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome. Crit Care Clin; Apr;36(2):415–26.

Valade S, Azoulay E, Galicier L, et al. Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis. Medicine (Baltimore; Oct;94(40):e1692. DOI: https://doi.org/10.1097/MD.0000000000001692

Dong J, Xie F, Jia L, et al. Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis. Sci Rep [Internet; May 31;9(1):8125, https://www.nature.com/articles/s41598-019-43909-w. DOI: https://doi.org/10.1038/s41598-019-43909-w

Lin S, Li Y, Long J, et al. Acute liver failure caused by hemophagocytic lymphohistiocytosis in adults. Medicine (Baltimore) [Internet, https://journals.lww.com/00005792-201611220-00035.

Aulagnon F, Lapidus N, Canet E, et al. Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis [Internet; Jun;65(6):851–9, http://www.ncbi.nlm.nih.gov/pubmed/25480521. DOI: https://doi.org/10.1053/j.ajkd.2014.10.012

Song Y, Pei R-J, Wang Y-N, et al. Central Nervous System Involvement in Hemophagocytic Lymphohistiocytosis in Adults. Chin Med J (Engl; Apr 5;131(7):776–83. DOI: https://doi.org/10.4103/0366-6999.228234

Kim M-M, Yum M-S, Choi H-W, et al. Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis. Korean J Hematol; 47. DOI: https://doi.org/10.5045/kjh.2012.47.4.273

Parodi A, Davì S, Pringe AB, et al. Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. DOI: 10.1002/art.24883. DOI: https://doi.org/10.1002/art.24883

Henter JI, Aricò M, Egeler RM. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol; 28. DOI: https://doi.org/10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.3.CO;2-Y

H HA, M A. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood; 118.

Marsh RA, Haddad E. How i treat primary haemophagocytic lymphohistiocytosis. Br J Haematol; 182. DOI: https://doi.org/10.1111/bjh.15274

Machaczka M, Nahi H, Karbach H. Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. Med Oncol; 29. DOI: https://doi.org/10.1007/s12032-011-9963-3

Yu JT, Wang CY, Yang Y. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol; 92. DOI: https://doi.org/10.1007/s00277-013-1784-3

Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes & Immunity 2012 13:4 2012; 13: 289–298. DOI: https://doi.org/10.1038/gene.2012.3

S CA, D G. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol; 38.

Minoia F, Davì S, Horne A. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol; 66.

Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol; 10. DOI: https://doi.org/10.1111/j.1462-5822.2008.01146.x

Bogdan C, Röllinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol; 28. DOI: https://doi.org/10.1016/S0020-7519(97)00169-0

Trottestam H, Horne AC, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011; 118: 4577. DOI: https://doi.org/10.1182/blood-2011-06-356261

Boraschi D. What Is IL-1 for? The Functions of Interleukin-1 Across Evolution. Front Immunol; 13. Epub ahead of print 6 April 2022. DOI: 10.3389/FIMMU.2022.872155. DOI: https://doi.org/10.3389/fimmu.2022.872155

Zinter MS, Hermiston ML. Calming the storm in HLH. Blood [Internet; Jul 11;134(2):103–4, https://ashpublications.org/blood/article/134/2/103/260676/Calming-the-storm-in-HLH. DOI: https://doi.org/10.1182/blood.2019001333

Charlesworth JEG, Wilson S, Qureshi A, et al. Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children. Pediatr Blood Cancer [Internet, https://onlinelibrary.wiley.com/doi/10.1002/pbc.29102.

Phadke O, Rouster-Stevens K, Giannopoulos H, et al. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol [Internet; Dec 29;19(1):98, https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-021-00585-3. DOI: https://doi.org/10.1186/s12969-021-00585-3

Naymagon L. Anakinra for the treatment of adult secondary HLH: a retrospective experience. Int J Hematol [Internet; Dec 10;116(6):947–55, https://link.springer.com/10.1007/s12185-022-03430-9. DOI: https://doi.org/10.1007/s12185-022-03430-9

Bami S, Vagrecha A, Soberman D, et al. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer [Internet, https://onlinelibrary.wiley.com/doi/10.1002/pbc.28581.

Kim JY, Kim M, Park JK, et al. Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study. Orphanet J Rare Dis [Internet, https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02516-1.

Rosée P La, Horne AC, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133: 2465–2477. DOI: https://doi.org/10.1182/blood.2018894618

Dufranc E, Del Bello A, Belliere J, et al. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome. Crit Care [Internet; Dec 22;24(1):166, https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02878-7. DOI: https://doi.org/10.1186/s13054-020-02878-7

Y. J, T. H, A. B, et al. Should We Stimulate or Suppress Immune Responses In Covid-19? Cytokine And Anti-cytokine Interventions. Autoimmun Rev; 19. DOI: 10.1016/j.autrev.2020.102567. DOI: https://doi.org/10.1016/j.autrev.2020.102567

Q. Z, A. W, H. M, et al. A Pilot Study Of Ruxolitinib As a Front-line Therapy For 12 Children With Secondary Hemophagocytic Lymphohistiocytosis. haematol; 106: 1892–1901. DOI: https://doi.org/10.3324/haematol.2020.253781

Wang J, Wang Z. Multicenter Study of Ruxolitinibcombined DEP Regimen As a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis. Blood 2019; 134: 1042–1042. DOI: https://doi.org/10.1182/blood-2019-130980

Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood, The Journal of the American Society of Hematology.

Wegehaupt O, Wustrau K, Lehmberg K, et al. Cell Versus Cytokine – Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity. Front Immunol 2020; 11: 503418. DOI: https://doi.org/10.3389/fimmu.2020.00808

Moshous D, Briand C, Castelle M, et al. Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis. Blood 2019; 134: 80–80. DOI: https://doi.org/10.1182/blood-2019-124477

Marsh RA, Allen CE, Mcclain KL, et al. Salvage Therapy of Refractory Hemophagocytic Lymphohistiocytosis with Alemtuzumab. Pediatr Blood Cancer 2013; 60: 101. DOI: https://doi.org/10.1002/pbc.24188

Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol 2017; 8: 561. DOI: https://doi.org/10.3389/fphar.2017.00561

He Y, Gao Y, Ping L, et al. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Cancer Res Clin Oncol 2023; 149: 2017–2027. DOI: https://doi.org/10.1007/s00432-022-04147-2

Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood 2020; 135: 826–833. DOI: https://doi.org/10.1182/blood.2019003886

Zhang L, Zhou J, Sokol L. Hereditary and Acquired Hemophagocytic Lymphohistiocytosis. Cancer Control [Internet; Oct 1;21(4):301–12. DOI: 10.1177/107327481402100406. DOI: https://doi.org/10.1177/107327481402100406

Janka G, Lehmberg K. Hemophagocytic syndromes — An update. Blood Reviews [Internet; Jul 1;28(4):135–42. DOI: 10.1016/j.blre.2014.03.002. DOI: https://doi.org/10.1016/j.blre.2014.03.002

Ehl S, Astigarraga I, Bahr Greenwood T, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. The Journal of Allergy and Clinical Immunology: In Practice [Internet; 1;6(5):1508–17. DOI: 10.1016/j.jaip.2018.05.031. DOI: https://doi.org/10.1016/j.jaip.2018.05.031

A. W, R. J, M.B. How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis? Curr Treat Options Neurol; 19, 3. DOI: 10.1007/s11940-017-0439-4. DOI: https://doi.org/10.1007/s11940-017-0439-4

Kuter DJ, Berliner N. Hemophagocytic Lymphohistiocytosis. Annual Review of Pathology-mechanisms of Disease [Internet; Jan 24;13(1):27–49. DOI: 10.1146/annurev-pathol-020117-043625. DOI: https://doi.org/10.1146/annurev-pathol-020117-043625

Chandrakasan S, Filipovich AH. Hemophagocytic Lymphohistiocytosis: Advances in Pathophysiology, Diagnosis, and Treatment. The Journal of Pediatrics [Internet. DOI: 10.1016/j.jpeds.2013.06.053. DOI: https://doi.org/10.1016/j.jpeds.2013.06.053

Ferreira RA, Vastert SJ, Abinun M, et al. Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis. Bone Marrow Transplantation 2006 38:3 2006; 38: 249–251. DOI: https://doi.org/10.1038/sj.bmt.1705415

Valade S, Mariotte E, Azoulay E. Coagulation Disorders in Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome. Crit Care Clin 2020; 36: 415–426. DOI: https://doi.org/10.1016/j.ccc.2019.12.004

Bayram C, Tahtakesen TN, Arslantaş E, et al. Prognostic Factors and Long-term Outcomes in 41 Children With Primary Hemophagocytic Lymphohistiocytosis: Report of a Single-center Experience and Review of the Literature. J Pediatr Hematol Oncol. DOI: 10.1097/MPH.0000000000002653. DOI: https://doi.org/10.1097/MPH.0000000000002653

Kaya Z, Bay A, Albayrak M, et al. Prognostic factors and long-term outcome in 52 Turkish children with hemophagocytic lymphohistiocytosis. Pediatric Critical Care Medicine; 1;16(6):e165-73. DOI: https://doi.org/10.1097/PCC.0000000000000449

Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica; Feb;89(2):183-8.

Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 2015; 125: 1548–1552. DOI: https://doi.org/10.1182/blood-2014-10-602607

Harnchoowong S, Soponkanaporn S, Vilaiyuk S, et al. Central nervous system involvement and thrombocytopenia as predictors of mortality in children with hemophagocytic lymphohistiocytosis. Front Pediatr; 10. DOI: https://doi.org/10.3389/fped.2022.941318

Goldman J, Desai MS, McClain KL, et al. Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med; Oct;19(10):e522-e530. DOI: 10.1097/PCC.0000000000001684. DOI: https://doi.org/10.1097/PCC.0000000000001684

Home | ClinicalTrials.gov, https://clinicaltrials.gov/ (accessed 6 September 2023).